bioRxivNeurosciencePreprint
TDP43 autoregulation gives rise to shortened isoforms that are tightly controlled by both transcriptional and post-translational mechanisms
Megan M. DykstraiD, Kaitlin WeskampiD, Nicolás GómeziD, Jacob Waksmacki, Elizabeth M.H. TankiD, M. Rebecca GlineburgiD, Allison G. Snyder, Emile S. PinarbasiiD, Michael E. BekieriD, Xingli LiiD, Jen Bai, Shameena Shahzad, Juno Nedumaran, Clare M. WielandiD, Corey Stewart, Sydney WilleyiD, Nikolas GrotewoldiD, Jonathon P. McBrideiD, John J. M. Moran, Aditya V. Suryakumar, Michael Lucas, Peter M. TessieriD, Michael Emmerson WardiD, Peter K. ToddiD, Sami J. BarmadaiD
Abstract
The nuclear RNA-binding protein TDP43 is integrally involved in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Previous studies uncovered N-terminal TDP43 isoforms that are predominantly cytosolic in localization, highly prone to aggregation, and enriched in susceptible spinal motor neurons. In healthy cells, however, these shortened (s)TDP43 isoforms are difficult to detect in comparison to full-length (fl)TDP43, raising questions regarding their origin and selective regulation. Here, we show that sTDP43 is created as a byproduct of TDP43 autoregulation and cleared by nonsense mediated RNA decay (NMD). The sTDP43-encoding transcripts that escape NMD can lead to toxicity but are rapidly degraded post-translationally. Circumventing these regulatory mechanisms by overexpressing sTDP43 results in neurodegeneration in vitro and in vivo via N-terminal oligomerization and impairment of flTDP43 splicing activity, in addition to RNA binding-dependent gain-of-function toxicity. Collectively, these studies highlight endogenous mechanisms that tightly regulate sTDP43 expression and provide insight into the consequences of aberrant sTDP43 accumulation in disease.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Export-biased, 3'UTR-preserving TDP-43 model links nuclear loss to cytoplasmic aggregation in ALS/FTLD
Genri Toyama, Shingo Koide, … Akihiro Sugai·bioRxiv·Nov 12, 2025
- Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS
Kaitlin Weskamp, Elizabeth M.H. Tank, … Sami J. Barmada·Journal of Clinical InvestigationPeer-reviewed·Nov 12, 2019
- Inhibition of nonsense-mediated decay in TDP-43 deficient neurons reveals novel cryptic exons
Irika R. Sinha, Yingzhi Ye, … Jonathan P. Ling·bioRxiv·Jun 28, 2025
- RNA-deficient TDP-43 causes loss of free nuclear TDP-43 by sequestration
Sean S. Keating, Adekunle T. Bademosi, … Adam K. Walker·bioRxiv·Sep 6, 2022
- TDP-43 toxic gain of function links ALS, FTD and Alzheimers Disease through splicing dysregulation
Welmoed van Zuiden, Thea Deborah Meimoun, … Eran Hornstein·bioRxiv·Apr 20, 2025
- SFPQ dysregulation promotes TDP-43 pathology through a pathogenic feedback loop
Alison L. Hogan, Patrick Chiu, … Marco Morsch·bioRxiv·Jul 25, 2026